Short Interest in Immix Biopharma, Inc. (NASDAQ:IMMX) Declines By 7.6%

Immix Biopharma, Inc. (NASDAQ:IMMXGet Free Report) was the target of a significant decrease in short interest in May. As of May 31st, there was short interest totalling 338,700 shares, a decrease of 7.6% from the May 15th total of 366,500 shares. Based on an average trading volume of 134,900 shares, the days-to-cover ratio is currently 2.5 days. Currently, 2.2% of the company’s stock are short sold.

Immix Biopharma Stock Down 0.5 %

IMMX traded down $0.01 during midday trading on Tuesday, hitting $2.04. The company had a trading volume of 403 shares, compared to its average volume of 211,141. The stock’s 50 day moving average price is $2.25 and its 200 day moving average price is $3.59. Immix Biopharma has a 52 week low of $1.55 and a 52 week high of $7.75. The company has a market capitalization of $53.88 million, a price-to-earnings ratio of -2.20 and a beta of 0.21.

Immix Biopharma (NASDAQ:IMMXGet Free Report) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Research analysts predict that Immix Biopharma will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in IMMX. Tocqueville Asset Management L.P. grew its stake in shares of Immix Biopharma by 89.0% in the 1st quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after acquiring an additional 17,800 shares in the last quarter. Tritonpoint Wealth LLC purchased a new stake in Immix Biopharma during the first quarter worth about $75,000. Jump Financial LLC bought a new stake in Immix Biopharma in the fourth quarter worth about $128,000. Private Advisor Group LLC bought a new position in shares of Immix Biopharma during the 4th quarter valued at approximately $690,000. Finally, OLD National Bancorp IN bought a new position in Immix Biopharma during the fourth quarter valued at $69,000. 11.26% of the stock is owned by institutional investors.

Immix Biopharma Company Profile

(Get Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Further Reading

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with's FREE daily email newsletter.